Hospitalisations in patients with idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry and EMPIRE Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F26%3A10001476" target="_blank" >RIV/00064190:_____/26:10001476 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1183/23120541.00402-2025" target="_blank" >https://doi.org/10.1183/23120541.00402-2025</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1183/23120541.00402-2025" target="_blank" >10.1183/23120541.00402-2025</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hospitalisations in patients with idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry and EMPIRE Registry

Popis výsledku v původním jazyce

Background We used data from the European MultiPartner IPF Registry (EMPIRE) and the US Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) Registry to examine the frequency of hospitalisation, risk factors associated with hospitalisation, and whether hospitalisation affected 5-year mortality in patients with idiopathic pulmonary fibrosis (IPF). Methods Data from January 2015 to September 2022 in EMPIRE and from June 2014 to December 2023 in the IPF-PRO Registry were analysed. Rates of hospitalisation and death were estimated using the Kaplan-Meier method. Associations between patient characteristics at enrolment and time to hospitalisation were assessed using Cox regression. Results The EMPIRE and IPF-PRO Registry cohorts comprised 2989 and 1001 patients, respectively. Median follow-up was 36.5 months in EMPIRE and 60 months in the IPF-PRO Registry. Overall, 20.3% of patients in EMPIRE and 70.3% (28.2% over 36 months) in the IPF-PRO Registry had one or more hospitalisation during follow-up. In both registries, lower percentage predicted diffusing capacity of the lungs for carbon monoxide and use of supplemental oxygen at enrolment were associated with an increased risk of hospitalisation in multivariable models. 5-year mortality did not differ between patients who were and were not hospitalised in EMPIRE (54.3% and 53.7%, respectively) or in the IPF-PRO Registry (51.7% and 46.1%, respectively). Conclusions Data from EMPIRE and the IPF-PRO Registry demonstrate the high risk of hospitalisations and mortality among patients with IPF and suggest there may be differences across countries in risk of hospitalisation. Variability in data collection, healthcare systems and clinical practices should be considered when interpreting differences between countries. (C) The authors 2026.

Název v anglickém jazyce

Hospitalisations in patients with idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry and EMPIRE Registry

Popis výsledku anglicky

Background We used data from the European MultiPartner IPF Registry (EMPIRE) and the US Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) Registry to examine the frequency of hospitalisation, risk factors associated with hospitalisation, and whether hospitalisation affected 5-year mortality in patients with idiopathic pulmonary fibrosis (IPF). Methods Data from January 2015 to September 2022 in EMPIRE and from June 2014 to December 2023 in the IPF-PRO Registry were analysed. Rates of hospitalisation and death were estimated using the Kaplan-Meier method. Associations between patient characteristics at enrolment and time to hospitalisation were assessed using Cox regression. Results The EMPIRE and IPF-PRO Registry cohorts comprised 2989 and 1001 patients, respectively. Median follow-up was 36.5 months in EMPIRE and 60 months in the IPF-PRO Registry. Overall, 20.3% of patients in EMPIRE and 70.3% (28.2% over 36 months) in the IPF-PRO Registry had one or more hospitalisation during follow-up. In both registries, lower percentage predicted diffusing capacity of the lungs for carbon monoxide and use of supplemental oxygen at enrolment were associated with an increased risk of hospitalisation in multivariable models. 5-year mortality did not differ between patients who were and were not hospitalised in EMPIRE (54.3% and 53.7%, respectively) or in the IPF-PRO Registry (51.7% and 46.1%, respectively). Conclusions Data from EMPIRE and the IPF-PRO Registry demonstrate the high risk of hospitalisations and mortality among patients with IPF and suggest there may be differences across countries in risk of hospitalisation. Variability in data collection, healthcare systems and clinical practices should be considered when interpreting differences between countries. (C) The authors 2026.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2026

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ERJ open research

ISSN

2312-0541

e-ISSN

—

Svazek periodika

12

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

nestránkováno

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-105032841408